Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

30 Nov 2022

Abstract excerpt

Approximately a quarter of men with metastatic castrate resistant prostate cancer (mCRPC) have alterations in homologous recombination repair (HRR). These patients exhibit enhanced sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Leveraging the synthetic lethality between PARP inhibition and HRR deficiency, studies have established marked clinical benefit and a survival advantage from PARP inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36497408
DOI: 10.3390/cancers14235922

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerPMID 36497408Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical DevelopmentSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancerSemantic proximity Read ↗

PARP inhibitors for homologous recombination-deficient prostate cancer.Semantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

Advances in PARP Inhibitors for Prostate CancerSemantic proximity Read ↗

Changing the History of Prostate Cancer with New Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.